ArticleBMC nephrology2026
Renal salt-wasting syndrome with tubular copper deposition in a heterozygous ATP7B carrier: a case report.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Copper Metabolism-Related Cell Death in Kidney Diseases: Molecular Mechanisms, Disease-Specific Evidence, and Translational Implications.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundATP7B mutations classically lead to Wilson’s disease, characterized by hepatic and neurological involvement due to systemic copper overload. However, renal-limited phenotypes are extremely rare, easily overlooked and clinically diverse. Here, we report a woman carrying a heterozygous ATP7B variant who presented with isolated salt-wasting syndrome, marked renal copper deposition. CASE PRESENTATION: We report a 30-year-old Chinese woman with renal salt-wasting syndrome and chronic kidney disease, without hepatic, neurological, or ophthalmologic abnormalities. Laboratory tests, including ceruloplasmin (0.20 g/L), 24-h urinary copper (20.8 µg/24 h), and liver function were within normal or borderline ranges, not fulfilling Wilson’s disease diagnostic criteria (Leipzig score < 4). Renal biopsy revealed marked copper accumulation within tubular epithelial cells, and immunohistochemistry showed reduced ATP7B expression. Whole-exome sequencing identified a heterozygous ATP7B mutation (c.2621 C > T, p.Ala874Val). Given the absence of systemic copper overload, the patient was treated with corticosteroids and electrolyte replacement rather than copper-chelating agents, leading to partial clinical improvement.
conclusionThis case suggests a possible renal-limited phenotype in an ATP7B carrier, underscoring the importance of integrating genetic testing and histopathology in unexplained tubulointerstitial nephritis. Long-term follow-up is essential to monitor for potential systemic manifestations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.